South Korean startup ILIAS Biologics has signed a Memorandum of Understanding (MoU) with HK inno.N for joint research to develop new biomedicine competitors.
With this MoU, the two organizations intend to team up – to find and develop new drug competitors using exosomes, known as the next game-changer in the drug delivery system.
The MoU raises expectations on the synergy of ILIAS’s versatile exosome platform technologies with gigantic expandability and HK inno.N’s broad new drug development know-how.
ILIAS Biologics has an exosome platform technology that can load a polymer drug in a free form inside the exosome and deliver it steadily inside the target cell. It has related technology patents in five nations including the United States, Japan, and China, and has recently been approved for a phase 1 clinical trial in Australia for an exosome-based anti-inflammatory drug candidate.
HK Inno.N, one more startup situated in South Korea, plans to create an exosome therapy for chronic diseases and acute respiratory infections, centered on the bio research center, and reinforce the new biopharmaceutical pipeline.